Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.01, Briefing.com reports. During the same quarter last year, the firm posted ($0.73) earnings per share.
Rocket Pharmaceuticals Trading Down 1.6 %
Shares of Rocket Pharmaceuticals stock opened at $22.98 on Thursday. Rocket Pharmaceuticals has a 52-week low of $14.89 and a 52-week high of $32.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.80 and a current ratio of 7.80. The firm has a 50-day moving average of $25.47 and a 200-day moving average of $25.77. The stock has a market cap of $2.09 billion, a PE ratio of -8.01 and a beta of 1.12.
Insider Buying and Selling at Rocket Pharmaceuticals
In related news, Director Gotham Makker sold 274,000 shares of the company’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $28.43, for a total transaction of $7,789,820.00. Following the completion of the sale, the director now owns 365,912 shares of the company’s stock, valued at $10,402,878.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director David P. Southwell sold 10,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $24.05, for a total value of $240,500.00. Following the completion of the transaction, the director now owns 114,784 shares of the company’s stock, valued at $2,760,555.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gotham Makker sold 274,000 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $28.43, for a total transaction of $7,789,820.00. Following the sale, the director now directly owns 365,912 shares in the company, valued at $10,402,878.16. The disclosure for this sale can be found here. Insiders sold 414,935 shares of company stock valued at $11,476,424 in the last quarter. Company insiders own 31.10% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Research Report on RCKT
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Featured Stories
- Five stocks we like better than Rocket Pharmaceuticals
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Electronic Arts Earnings Engaging Players and Building Value
- 10 Best Airline Stocks to Buy
- 3 Tripe-Digit Growth Mid Cap Stocks to Watch This Quarter
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Has FMC Stock Reached Bottom? First Quarter Earnings Say Yes
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.